Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $100.00 at HC Wainwright

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price lowered by HC Wainwright from $110.00 to $100.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently commented on RYTM. Needham & Company LLC cut their price target on Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a report on Tuesday. Bank of America decreased their price objective on Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating on the stock in a report on Tuesday. Guggenheim boosted their price objective on Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Citizens Jmp cut their target price on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating for the company in a research note on Tuesday. Finally, The Goldman Sachs Group raised their target price on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.13.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM opened at $85.86 on Wednesday. The firm’s 50-day moving average is $99.45 and its 200-day moving average is $102.69. Rhythm Pharmaceuticals has a 52-week low of $45.90 and a 52-week high of $122.20. The company has a market cap of $5.86 billion, a price-to-earnings ratio of -27.61 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business had revenue of $57.25 million during the quarter, compared to analysts’ expectations of $56.16 million. During the same quarter last year, the company earned ($0.72) earnings per share. The firm’s revenue was up 36.9% on a year-over-year basis. Equities analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Activity at Rhythm Pharmaceuticals

In related news, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the transaction, the chief financial officer owned 110,512 shares in the company, valued at $11,190,445.12. This trade represents a 3.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the sale, the chief accounting officer directly owned 160 shares in the company, valued at approximately $14,329.60. This represents a 97.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 27,267 shares of company stock worth $2,719,955. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Rhythm Pharmaceuticals by 39.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after purchasing an additional 1,407,313 shares in the last quarter. RA Capital Management L.P. increased its position in shares of Rhythm Pharmaceuticals by 17.3% during the 4th quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after purchasing an additional 985,478 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Rhythm Pharmaceuticals by 1,493.8% during the 3rd quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after purchasing an additional 918,212 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Rhythm Pharmaceuticals by 445.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 783,559 shares of the company’s stock valued at $49,513,000 after purchasing an additional 639,919 shares during the last quarter. Finally, Capital Research Global Investors acquired a new position in Rhythm Pharmaceuticals in the third quarter valued at about $60,417,000.

Key Headlines Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.